Afnan Alshnbari
Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19?–Targeting hyperinflammation
Alshnbari, Afnan; Idris, Iskandar
Abstract
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are antidiabetic drugs with numerous pleiotropic and positive clinical effects, particularly regarding a reno-cardiovascular protective effect. More recent studies, including from our laboratory, have highlighted some novel anti-inflammatory activity of SGLT-2 inhibitors. This may confer a theoretical advantage in mitigating excessive cytokine production and inflammatory response associated with serious COVID-19 infection. Specifically, earlier research has demonstrated that SGLT-2 inhibitors are associated with a notable decrease in inflammatory indicators, for example, C-reactive protein, ferritin, and interleukin-6. Furthermore, SGLT-2 inhibitors exhibit a favourable impact on the vascular endothelium function; this could pertinence the prophylaxis of the thrombotic issues that arise in SARS-CoV-2. This review provides an overview of the COVID-19 indirect immune response mechanisms impacting the cardiovascular system and the possible effect of SGLT-2 inhibitors on the management of COVID-19.
Journal Article Type | Article |
---|---|
Acceptance Date | Jan 6, 2022 |
Online Publication Date | Jan 20, 2022 |
Publication Date | Jan 1, 2022 |
Deposit Date | Jan 11, 2022 |
Publicly Available Date | Jan 2, 2023 |
Journal | Current Medical Research and Opinion |
Print ISSN | 0300-7995 |
Electronic ISSN | 1473-4877 |
Peer Reviewed | Peer Reviewed |
Volume | 38 |
Issue | 3 |
Pages | 357-364 |
DOI | https://doi.org/10.1080/03007995.2022.2027141 |
Public URL | https://nottingham-repository.worktribe.com/output/7222089 |
Publisher URL | https://www.tandfonline.com/doi/full/10.1080/03007995.2022.2027141 |
Additional Information | This is an Accepted Manuscript of an article published by Taylor & Francis in Current Medical Research and Opinion on 20 Jan 2022, available online: https://www.tandfonline.com/10.1080/03007995.2022.2027141 |
Files
COVID-19 And SGLT2 Inhibitor (8) II CLEAN
(489 Kb)
PDF
You might also like
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search